We would like to thank Professor Cusi1 for pointing out the omission of the important randomised controlled trial,2 in which he and his colleagues have essentially confirmed and consolidated the proof for the effectiveness of pioglitazone in treating non-alcoholic steatohepatitis (NASH). We agree with Professor Cusi that pioglitazone could be considered a valid and effective treatment option for patients with NASH, although effectiveness has to be weighed against the concerns about its long-term safety. We can only hope that our review3 and his commentary on it will enhance awareness and raise the current limited acceptance of its use.4
Contributors
YR and AJS wrote the text jointly.
Funding
National Institute of Diabetes and Digestive and Kidney Diseases (Intramural Research Program).
Competing interests
AS: Consultant for Echosens-Sandhil and Sequana.
Provenance and peer review
Not commissioned; internally peer reviewed.
Intramural Research ProgramNational Institute...
https://ift.tt/2kW7u8g
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.